Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.

[1]  J. Hsia,et al.  Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.

[2]  S. Hanson,et al.  Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Hirsh,et al.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. , 1992, The Biochemical journal.

[4]  J. Loscalzo,et al.  Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. , 1992, Circulation research.

[5]  D. Collen,et al.  Plasma Fibrinopeptide A Levels in Patients With Acute Myocardial Infarction Treated With Alteplase: Correlation With Concomitant Heparin, Coronary Artery Patency, and Recurrent Ischemia , 1992, Circulation.

[6]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[7]  J. Eidt,et al.  Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. , 1992, The American journal of physiology.

[8]  J. Maraganore,et al.  Structure‐function relationships of hirulog peptide interactions with thrombin , 1991, FEBS letters.

[9]  A. Tulinsky,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991, Journal of molecular biology.

[10]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[11]  Burton E. Sobel,et al.  Relative Efficacy of Antithrombin Compared With Antiplatelet Agents in Accelerating Coronary Thrombolysis and Preventing Early Reocclusion , 1991, Circulation.

[12]  J. Hirsh.  Drug therapy : heparin , 1991 .

[13]  D. Tate,et al.  Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[14]  W J Penny,et al.  Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. , 1990, Circulation.

[15]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[16]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[17]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[18]  A. Haeberli,et al.  Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. , 1989, Circulation.

[19]  R. Peters,et al.  Recombinant Desulphatohirudin (CGP 39393) Anticoagulant and Antithrombotic Properties In Vivo , 1989, Thrombosis and Haemostasis.

[20]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[21]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[22]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[23]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[24]  P. Théroux,et al.  Fibrinopeptide A and platelet factor levels in unstable angina pectoris. , 1987, Circulation.

[25]  L. Fleisher,et al.  Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. , 1984, Circulation.

[26]  R. Tallarida,et al.  Manual of Pharmacologic Calculations: With Computer Programs , 1984 .

[27]  D. Berman,et al.  Intracoronary thrombolysis in evolving myocardial infarction. , 1981, American heart journal.

[28]  J. Soria,et al.  A solid phase immuno enzymological assay for the measurement of human fibrinopeptide A. , 1980, Thrombosis research.